China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a strategic licensing agreement with Colombia-headquartered Laboratorios Legrand S.A. Under this agreement, Laboratorios Legrand will manage the regulatory filing and commercialization of Mabwell’s biosimilars, MAILISHU and 9MW0321, which are both biosimilars of denosumab. This deal specifically covers the territories of Colombia and Ecuador.
Denosumab: A Key Treatment in Fracture Prevention
Denosumab, a novel RANKL inhibitor developed by Amgen, is currently marketed in China by BeiGene. It has shown significant efficacy in reducing the risk of multiple fractures, including vertebral, non-vertebral, and hip fractures. MAILISHU received approval from the China National Medical Products Administration (NMPA) in March 2023, while 9MW0321 has been filed for marketing authorization approval.
Expanding Global Reach
This licensing agreement expands Mabwell’s global footprint, following a similar arrangement earlier this year with Searle Co., Ltd., a strategic partner in Egypt and Pakistan, for the licensing rights to both MAILISHU and 9MW0321. Mabwell continues to focus on enhancing its presence in international markets, aiming to provide access to its innovative biosimilar products.-Fineline Info & Tech
